Development of 2,4-diaminopyrimidine derivatives as novel SNSR4 antagonists

https://doi.org/10.1016/j.bmcl.2011.01.138Get rights and content

Abstract

2,4-Diaminopyrimidines derivatives were developed as a novel class of SNSR4 antagonists. Structure activity relationship of the diamino pyrimidine core was explored and a tool compound suitable for target validation was identified.

Reference and notes (7)

  • M.J. Marinissen et al.

    Trends Pharmacol. Sci.

    (2001)
    J.M. Stadel et al.

    Trends Pharmacol. Sci.

    (1997)
    D.K. Rohrer et al.

    Physiol. Rev.

    (1998)
    A.L. Hopkins et al.

    Nat. Rev. Drug Discov.

    (2002)
  • X. Dong et al.

    Cell

    (2001)
  • P. Kunapuli et al.

    Anal. Biochem.

    (2006)
There are more references available in the full text version of this article.

Cited by (11)

  • MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs

    2022, Pharmacology and Therapeutics
    Citation Excerpt :

    Whereas a significant decrease in activity was reported in case of methylation at C5 of X1-26 (see Table 6), substitution at C6 with a methyl group was tolerated. The most potent and selective antagonist among these derivatives inhibited the BAM8-22-induced effects with an IC50 value of 14 nM determined in calcium assays (X1-26, Table 6) (Bayrakdarian, Butterworth, Hu, Santhakumar, & Tomaszewski, 2011). The signaling pathways of MRGPRX1 were investigated using in vitro assays involving heterologous expression in cell lines and rodent primary neuronal cell cultures, in addition to in vivo transgenic mouse models.

  • Atypical opioid receptors: unconventional biology and therapeutic opportunities

    2022, Pharmacology and Therapeutics
    Citation Excerpt :

    Several studies have already assessed the effects of modulating the aforementioned receptors with their canonical agonists and antagonists in relation to opioid-related functions. Only a few molecules targeting MgrX1 have been described, including three different antagonist scaffolds (Bayrakdarian, Butterworth, Hu, Santhakumar, & Tomaszewski, 2011; Kunapuli et al., 2006; Schmidt, Butterworth, O'Donnell, Santhakumar, & Tomaszewski, 2009) and so far, no selective agonist is available for this receptor. Interestingly, it was shown that the positive allosteric modulator of MrgX1, ML382, in the presence of the endogenous ligand BAM8-22, and to a lesser extent alone, attenuates persistent nociception without significant adverse effects in humanized mice which underwent chronic constriction injury (Li et al., 2017).

  • Effects of the mas-related gene (Mrg) C receptor agonist BAM6-22 on nociceptive reflex activity in naive, monoarthritic and mononeuropathic rats after intraplantar and intrathecal administration

    2016, European Journal of Pharmacology
    Citation Excerpt :

    From the perspective of potential therapeutic application, first studies exploring the role of MrgC receptors in nociception suggested that MrgC receptor antagonists might be effective analgesics as peripherally and centrally administered MrgC receptor agonists elicited pronociceptive effects in naïve rats (Cao et al., 2003; Grazzini et al., 2004). In fact, two groups reported on the discovery and structure-activity-relationship of small molecule MrgC receptor antagonists (Kunapuli et al., 2006; Bayrakdarian et al., 2011). This concept was further supported by the finding that activation of peripheral MrgX1 receptors by BAM8-22 elicited nociceptive sensations in healthy human volunteers (Sikand et al., 2011).

  • Peptidomimetics of Arg-Phe-NH<inf>2</inf> as small molecule agonists of Mas-related gene C (MrgC) receptors

    2014, Bioorganic and Medicinal Chemistry
    Citation Excerpt :

    Arg-Phe-NH2 and 1-adamantanecarbonyl-Arg-Phe-NH2 were purchased from Bachem Biosciences (King of Prussia, PA). Compounds 1c,11 25,20 and 2621 were prepared according to the previously reported procedures. A milky mixture of 2-(tert-butoxycarbonylamino)-2-(piperidin-4-yl)acetic acid 4 (0.5 g, 1.94 mmol, 1 equiv) and tert-butyl(1H-pyrazol-1-yl)methanediylidenedicarbamate 3 (0.72 g, 2.32 mmol, 1.2 equiv) in methanol (12 mL) was stirred at rt over 2 days.

View all citing articles on Scopus
View full text